Table 2 Patient and tumor characteristics for the ER+/HER2− subgroup (n = 236) by treatment arm
Characteristics | ER+/HER2– cohort (n = 236) | |
|---|---|---|
Control group n (%) | Tam-treated group n (%) | |
Age (years) | ||
 Median | 46 | 45 |
 Range | 27–54 | 33–57 |
Tumor size (mm) | ||
 ≤ 20 | 56 (45) | 43 (38) |
 > 20 | 68 (55) | 69 (62) |
Nodal status | ||
 Node-negative | 29 (23) | 31 (28) |
 Node-positive | 95 (77) | 81 (72) |
 N1 | 65 (52) | 58 (52) |
 N2 | 30 (24) | 23 (21) |
NHG | ||
 1 | 20 (16) | 19 (17) |
 2 | 72 (59) | 61 (56) |
 3 | 31 (25) | 30 (27) |
 Missing | 1 | 2 |
PR | ||
 Positive | 117 (94) | 100 (89) |
 Negative | 7 (6) | 12 (11) |
Ki67 (%) | ||
 Median | 27 | 26 |
 Range | 2–68 | 5–56 |
 Missing | 8 | 5 |
Histopathological type | ||
 Ductal/NST | 105 (85) | 94 (84) |
 Lobular | 13 (11) | 12 (11) |
 Medullary | 2 (2) | 1 (1) |
 Other | 3 (2) | 5 (5) |
 Missing | 1 | 0 |
TILs (%) | ||
 < 10 | 80 (65) | 83 (74) |
 10–49 | 34 (27) | 26 (23) |
 50–100 | 10 (8) | 3 (3) |
PAM50 subtype | ||
 Luminal A | 82 (66) | 66 (59) |
 Luminal B | 33 (27) | 36 (32) |
 HER2-enriched | 8 (7) | 4 (4) |
 Basal-like | 1 (1) | 6 (5) |